|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Department of Veterans Affairs |
|---|---|
| Collaborator: |
Oregon Health and Science University |
| Information provided by (Responsible Party): | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00129467 |
Purpose
The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
| Condition | Intervention |
|---|---|
|
Depression Palliative Care Cancer Mental Disorder |
Drug: Methylphenidate + SSRI Drug: SSRI + placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Methylphenidate for Depressed Cancer Patients in Hospice |
| Enrollment: | 46 |
| Study Start Date: | February 2005 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Subjects receiving SSRI + methylphenidate
|
Drug: Methylphenidate + SSRI
Subjects assigned to SSRI + methylphenidate will take methylphenidate 5 mg twice daily (8 AM and noon) for 3 days, then 2 capsules (10mg active ingredient) twice per day for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of study medication (methylphenidate 5mg at 8:00am or noon, or placebo), they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg. Similarly, subjects assigned to SSRI + placebo will receive 1 capsule of placebo twice daily (8 AM and noon) for 3 days and follow identical dose titration guidelines.
|
|
Placebo Comparator: 2
Subjects receiving SSRI + placebo
|
Drug: SSRI + placebo
Subjects assigned to SSRI + placebo will receive 1 capsule of placebo twice daily (8 AM and noon) for 3 days and follow identical dose titration guidelines.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inclusion:
Exclusion Criteria:
Exclusion:
Contacts and Locations| United States, Oregon | |
| Portland VA Medical Center | |
| Portland, Oregon, United States, 97239-2964 | |
| Principal Investigator: | Linda K. Ganzini, MD MPH | Portland VA Medical Center |
More Information
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00129467 History of Changes |
| Other Study ID Numbers: | IIR 03-194, 01153, 10-0603, CPC-04115-LX |
| Study First Received: | August 9, 2005 |
| Last Updated: | January 27, 2012 |
| Health Authority: | United States: Federal Government |
|
Depression Hospice Care Antidepressive Agents Methylphenidate |
Central Nervous System Stimulant Pain Caregiver Burden Cancer |
|
Mental Disorders Psychotic Disorders Depression Depressive Disorder Schizophrenia and Disorders with Psychotic Features Behavioral Symptoms Mood Disorders Central Nervous System Stimulants Methylphenidate Antidepressive Agents |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors |